Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities

European Journal of Public Health

Volumn 17, Issue 5, 2007, Pages 492-496

  Gnavi, Roberto ^a,d   Migliardi, Alessandro ^a   Demaria, Moreno ^b   Petrelli, Alessio ^a   Caprioglio, Adele ^a   Costa, Giuseppe ^a,c  

^a ASL 5 Regione Piemonte   (Italy)

^b Regional Enviromental Protection Agency of Piedmont   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d ASL 5   (Italy)

Author keywords

Coronary heart disease; Drug; Italy; Prescriptions; Socioeconomic factors; Statins

Indexed keywords

ATORVASTATIN;

ADULT; AGED; AGEISM; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY CARE UNIT; DATA BASE; DEMOGRAPHY; DRUG EFFICACY; FEMALE; HOSPITAL DISCHARGE; HUMAN; ISCHEMIC HEART DISEASE; ITALY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIOECONOMICS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DRUG UTILIZATION REVIEW; FEMALE; HEALTH CARE RATIONING; HEALTHCARE DISPARITIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PATIENT DISCHARGE; PHYSICIAN'S PRACTICE PATTERNS; SEX FACTORS; SOCIOECONOMIC FACTORS; URBAN HEALTH;

EID: 35648952129     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckm005     Document Type: Article

References (28)

1. Walley T, Folino-Gallo P, Schwabe U, et al. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005;60:543-51.
2. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-89.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med 1998;339:1349-57.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
6. Blauw GJ, Lagaay AM, Smelt AH, et al. Stroke, statins, and cholestrol: a meta-analysis of randomised, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-50.
7. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the prospective pravastatin pooling (PPP) Project. Circulation 2001;103:387-92.
8. Euroaspire I and II group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
9. DeWilde S, Carey IM, Bremmer SA, et al. Evolution of statin prescribing 1994-2001: a case of agism but not sexism?. Heart 2003;89:417-21.
10. Hippisley-Cox J, Pringle M, Crown N, et al. Sex inequalities in ishaemic heart disease in general practice: cross sectional survey. BMJ 2001;322:1-5.
11. Whincup P, Emberson J, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002;88:25-29.
12. Reid FDA, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002;88:15-19.
13. Ward PR, Noyce PR, St Leger AS. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health 2004;58:89-96.
14. Marinacci C, Spadea T, Biggeri A, et al. The role of individual and contextual socioeconomic circumstances on mortality: analysis of time variations in a city of north west Italy. J Epidemiol Community Health 2004;58:199-207.
15. Skov T, Deddens J, Petersen MR, et al. Prevalence proportion ratios: estimation and hypotesis testing. Int J Epidemiol 1998;27:91-95.
16. Ferrario M, Cesana G, Vanuzzo D, et al. Surveillance of ischaemic heart disease: results from the Italian MONICA populations. Int J Epidemiol 2001;30:S23-S29.
17. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001;22:554-72.
18. Carroll K, Majeed A, Firth C, et al. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Publ Health Med 2003;25:29-35.
19. Hartz I, Eggen AE, Grimsgaard S, et al. Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromsø study 2001. Eur J Clin Pharmacol 2004;60:643-49.
20. Rasmussen JN, Gislason GH, Abildstrom SZ, et al. Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Clin Pharmacol 2005;60:150-58.
21. Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Pub Health Med 2000;22:275-79.
22. Williams D, Bennett K, Feely J. Evidence of an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003;55:604-8.
23. Joung IM, Stronks K, van de Mheen H, et al. Health behaviours explain part of the differences in self reported health associated with partner/marital status in The Netherlands. J Epidemiol Community Health 1995;49:482-88.
24. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA 1998;279:1458-62.
25. Bellotti P, Badano LP, Acquarone N, et al. Specialists-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalised for heart failure: the OSCUR study. Eur Heart J 2001;22:596-604.
26. Jackevicius CA, Anderson GM, Leiter L, et al. Use of the statins in patients after acute myocardial infarction. Does evidence change practice? Arch Intern Med 2001;161:183-88.
27. Bowling A. Ageism in cardiology. BMJ 1999;319:1353-5.
28. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients. The treatment-risk paradox. JAMA 2004;291:1864-70.